Replies to post #798904 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

No I wasn’t

I changed it in some of you

and you are wrong about today’s PR as well. Instead, what it demonstrates is that it will:
The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined. In the meantime, I’m hoping they have something like CDF funds to work with, with b grade manufacturing, prior to NICE funding.

You’re misinterpreting today’s PR. The PR does not say “B-grade will continue commercially." as you claim It says the first Grade C suite will more than double the total capacity of the existing Grade B suites. That’s a classic description of a transition pathway, not a confirmation that B-grade will be the long-term commercial route.

The whole point of the C-suite expansion is that it will replace artisanal bottlenecks with automation-ready space (Flaskworks/Eden). Grade B remains necessary for certain aseptic steps, but it’s not the commercial bottleneck or the scalable production layer. The PR makes that very clear.

CDF before NICE is wishful thinking. CDF is only used when: NICE expects to recommend after more data, AND manufacturing/pricing is already viable, AND the commercial pathway is stable. Artisanal manufacturing alone does not meet those criteria. That’s why NWBO is building Grade C capacity and validating automated systems that’s the commercial route. The PR is 100% consistent with that.